关键词: GLP-1 receptor agonists SGLT-2 inhibitors beta cells cardiorenal axis kidney disease type 2 diabetes type 2 diabetes pharmacotherapy type 2 diabetes remission

Mesh : Diabetes Mellitus, Type 2 / therapy drug therapy Humans Blood Glucose / metabolism Hypoglycemic Agents / therapeutic use Insulin-Secreting Cells / metabolism drug effects Glycemic Control / methods Disease Management

来  源:   DOI:10.3389/fendo.2024.1394805   PDF(Pubmed)

Abstract:
Our understanding of type 2 diabetes (T2D) has evolved dramatically. Advances have upended entrenched dogmas pertaining to the onset and progression of T2D, beliefs that have prevailed from the early era of diabetes research-and continue to populate our medical textbooks and continuing medical education materials. This review article highlights key insights that lend new governing principles for gold standard management of T2D. From the historical context upon which old beliefs arose to new findings, this article outlines evidence and perspectives on beta cell function, the underlying defects in glucoregulation, the remediable nature of T2D, and, the rationale supporting the shift to complication-centric prescribing. Practical approaches translate this rectified understanding of T2D into strategies that fill gaps in current management practices of prediabetes through late type 2 diabetes.
摘要:
我们对2型糖尿病(T2D)的理解已经发生了巨大变化。进展已经颠覆了与T2D的发病和进展有关的根深蒂固的教条,从糖尿病研究的早期时代就盛行的信念-并继续填充我们的医学教科书和继续医学教育材料。本文重点介绍了关键见解,这些见解为T2D的黄金标准管理提供了新的治理原则。从旧信仰产生的历史背景到新发现,这篇文章概述了β细胞功能的证据和观点,葡萄糖调节的潜在缺陷,T2D的可修复性,and,支持转向以并发症为中心的处方的基本原理。实用的方法将这种对T2D的正确理解转化为策略,以填补当前糖尿病前期至晚期2型糖尿病的管理实践中的空白。
公众号